Source: Business Wire
AdvanCell Closes A$18M Series B Funding Led by Morningside
Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs.
